Genesia Ventures Invests in Perinatal Healthcare Startup nonat to Tackle Preterm Birth and Neonatal Mortality
Genesia Ventures announces its investment in the Pre-Series A round of nonat Inc., a healthcare startup developing medical AI foundation models and medical devices tailored to women and children. The investment was made through Genesia Venture Fund 4 (GV-4), with participation from NOBUNAGA Capital Village Co., Ltd.
Business Overview
nonat Inc. (Headquarters: Gifu, Japan; CEO: Keisuke Ito) is a digital health startup that aims to build a new healthcare model for women and children under the concept of “Generations as a Service.”
The company is developing medical AI foundation models and medical devices tailored to the needs of women and children. Its initial focus is on solving perinatal healthcare challenges such as preterm birth, stillbirth, and neonatal mortality—issues that require continuous data monitoring rather than fragmented evaluations from occasional prenatal checkups.
nonat’s proprietary AI foundation model is designed to visualize pregnancy conditions through complex biomarkers, enabling proactive care and risk detection. Since its founding in 2023, the company has completed proof-of-concept (PoC) studies through three clinical research projects, laying the groundwork for full-scale commercialization.
Use of Funds and Future Prospects
With this Pre-Series A funding, nonat will:
・Improve the generalization performance and data quality of its AI algorithms
・Expand its team recruitment, especially in clinical research and R&D
・Advance multi-institutional collaborative research with academic partners
The company aims to accelerate product development and clinical deployment in partnership with national universities and healthcare institutions.
About the Investment
Takashi Sogabe, Investment Manager, Genesia Ventures
nonat’s challenge—tackling perinatal care gaps—is deeply relevant not only in Japan, where maternity clinics are declining and rural depopulation is progressing, but also globally, amid rising maternal age and limited healthcare resources.
Their approach, combining AI and continuous biomarker monitoring, has the potential to reshape the entire structure of perinatal healthcare. We are particularly inspired by CEO Keisuke Ito’s global medical background and strong sense of mission. His leadership embodies the kind of founder we believe can bridge the gap between deep tech innovation and societal impact.
Genesia Ventures is committed to supporting nonat’s bold vision to ensure equitable, life-saving care for all women and children, regardless of background or circumstance.
Company Overview
Company Name: nonat Inc.
Website: https://nonat-home.com/en/
Established: February 2023
Headquarters:
•Gifu Office: Kawaharu Building 202, 5-15 Soden-Sakaemachi, Gifu-shi, Gifu 502-0847, Japan
•Tokyo Lab: Room 711, Lions Plaza Ebisu, 3-25-3 Higashi, Shibuya-ku, Tokyo 150-0011, Japan
Representative: CEO, Keisuke Ito
Business: Development of medical AI foundation models and perinatal health devices
